Neuland Laboratories Ltd.

BSE: 524558 NSE: NEULANDLAB
Neuland Laboratories Ltd. - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L85195TG1984PLC004393 Incorporated 07 January 1984 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: NEULANDLAB · BSE: 524558 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹2,022.99 Cr
▲ 36.98% YoY
Computed EBITDA · FY 2026
₹604.66 Cr
▲ 75.89% YoY
Net profit · FY 2026
₹364 Cr
▲ 39.94% YoY
Authorised capital
₹44 Cr
Registered with MCA
Paid-up capital
₹12.83 Cr
Issued & subscribed
Open charges
₹1,221.88 Cr
Satisfied ₹2,289.23 Cr
Company age
42 yrs
Est. 1984
Employees · EPFO
1,860
Latest available

About Neuland Laboratories Ltd.

Data last updated: 14 July 2026

Neuland Laboratories Ltd. is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 07 January 1984, the company has been in operation for over 42 years.

Registered with ROC Hyderabad under CIN L85195TG1984PLC004393. Listed on BSE: 524558 and NSE: NEULANDLAB.

Capital: an authorised share capital of ₹44 Cr and a paid-up capital of ₹12.83 Cr. Formerly known as Neuland Laboratories Private Limited. It is led by directors including Prasad Raghava Menon and Homi Rustam Khusrokhan.

Last AGM: 30 July 2025. Financial statements filed for year ended 31 March 2025. Office: Hyderabad, Telangana.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹2,022.99 Cr, a growth of 36.98% compared to the previous year. The net worth stands at ₹1,874.47 Cr (up 22.93% YoY). Total assets are valued at ₹2,930.14 Cr (up 34.42% YoY).

The company has a workforce of approximately 1,860 employees as per the latest available data.

The company is associated with 1 brand - Neuland Labs. As per MCA filings, the company has open charges of ₹1,221.88 Cr and satisfied charges of ₹2,289.23 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neulandlabs.com.

Company Details of Neuland Laboratories Ltd.
CIN L85195TG1984PLC004393
Registration Number 004393
Incorporation Date 07 January 1984
ROC Hyderabad
Listing Status Listed (BSE: 524558, NSE: NEULANDLAB)
Company Status Active
Date of Last AGM 30 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ramamohan Rao Davuluri Whole-Time Director Sucheth Rao Davuluri Whole-Time Director Saharsh Rao Davuluri Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    neulandlabs.com
  • Social Media
  • Registered Address
    11Th Floor (5Th Level) Phoenix Ivy Building Plot No. 573A – Iii Road No. 82 Jubilee, Hills, Hyderabad, Telangana, India – 500033
  • Industry
    Pharma, API Manufacturers
Company report
Neuland Laboratories Ltd. - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Neuland Laboratories Ltd. report

Financials, compliance, directors, charges, ownership and filings for Neuland Laboratories Ltd. in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has one previous CIN (Corporate Identification Number): L85195AP1984PLC004393. The current CIN is L85195TG1984PLC004393, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L85195TG1984PLC004393 Current
L85195AP1984PLC004393 Previous

Associated Brands with Neuland Laboratories Ltd.

Neuland Laboratories Ltd. operates one associated brand: Neuland Labs. These brands represent Neuland Laboratories Ltd.'s diversified market presence and brand portfolio.

Brand Description Website
Neuland Labs
Active pharmaceutical ingredients and peptides are manufactured globally. neulandlabs.com

Competitors & Alternatives of Neuland Laboratories Ltd.

Brands and companies operating in the same space as Neuland Laboratories Ltd. include Laurus Labs, Symbiotec, Sterling Pharma Solutions and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
ST PHARM ST PHARM Oligonucleotide, mRNA, and small molecule CDMO services are provided. - 2008
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Neuland Laboratories Ltd.

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is audited by M S K A & Associates LLP, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M S K A & Associates LLP, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is currently managed by 9 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Prasad Raghava Menon
Also directs: Chemplast Sanmar Limited, Data Patterns (India) Limited
Director 31 Oct 2022 3 Years 9 Months Current
Homi Rustam Khusrokhan
Also directs: Strides Pharma Science Limited, The Anglo Scottish Education Society
Director 12 Feb 2019 7 Years 6 Months Current
Ramamohan Rao Davuluri
Also directs: Pattancheru Enviro-Tech Limited
Whole-Time Director 07 Jan 1984 42 Years 7 Months Current
Sucheth Rao Davuluri
Also directs: Pattancheru Enviro-Tech Limited
Whole-Time Director 29 Jul 2003 23 Years 0 Months Current
Saharsh Rao Davuluri Whole-Time Director 01 Jun 2009 17 Years 2 Months Current
Ravi Shankar Gopinath
Also directs: Thermax Limited.
Director 01 Aug 2025 1 Years 0 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Neuland Laboratories Ltd. FY 2026 filings available

Neuland Laboratories Ltd. reported revenue of ₹2,022.99 Cr (up 36.98% YoY) for FY 2026.

Revenue · FY 2026
₹2,022.99 Cr ▲ 36.98%
Profit · FY 2026
₹364 Cr ▲ 39.94%
Computed EBITDA · FY 2026
₹604.66 Cr ▲ 75.89%
Revenue₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹763 Cr763FY 2020FY 2021: ₹937 Cr · +22.8% YoY937+22.8%FY 2021FY 2022: ₹951 Cr · +1.5% YoY951+1.5%FY 2022FY 2023: ₹1,191 Cr · +25.2% YoY1,191+25.2%FY 2023FY 2024: ₹1,559 Cr · +30.8% YoY1,559+30.8%FY 2024FY 2025: ₹1,477 Cr · -5.2% YoY1,477-5.2%FY 2025FY 2026: ₹2,023 Cr · +37% YoY2,023+37%FY 2026
Net Profit₹ Cr · Consolidated0200400FY 2020: ₹16 Cr16.2FY 2020FY 2021: ₹81 Cr · +397.4% YoY80.6+397.4%FY 2021FY 2022: ₹64 Cr · -20.8% YoY63.8-20.8%FY 2022FY 2023: ₹164 Cr · +156.2% YoY164+156.2%FY 2023FY 2024: ₹300 Cr · +83.5% YoY300+83.5%FY 2024FY 2025: ₹260 Cr · -13.3% YoY260-13.3%FY 2025FY 2026: ₹364 Cr · +39.9% YoY364+39.9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,000Q1'25: ₹440 Cr · +21.1% YoY440+21.1%Q1'25Q2'25: ₹311 Cr · -25.6% YoY311-25.6%Q2'25Q3'25: ₹398 Cr · +1.3% YoY398+1.3%Q3'25Q4'25: ₹328 Cr · -14.7% YoY328-14.7%Q4'25Q1'26: ₹293 Cr · -33.4% YoY293-33.4%Q1'26Q2'26: ₹514 Cr · +65.4% YoY514+65.4%Q2'26Q3'26: ₹440 Cr · +10.5% YoY440+10.5%Q3'26Q4'26: ₹776 Cr · +136.4% YoY776+136.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,022.99 Cr ₹1,476.84 Cr ₹1,558.58 Cr ₹1,191.2 Cr ₹951.08 Cr ₹936.91 Cr ₹762.71 Cr
Other Income ₹30.17 Cr ₹20.51 Cr ₹12.54 Cr ₹9.75 Cr ₹2.08 Cr ₹16.1 Cr ₹3.89 Cr
Total Income ₹2,053.15 Cr ₹1,497.35 Cr ₹1,571.12 Cr ₹1,200.95 Cr ₹953.15 Cr ₹953.01 Cr ₹766.6 Cr
Cost of Materials Consumed ₹819.76 Cr ₹574.81 Cr ₹632.43 Cr ₹487.74 Cr ₹437.55 Cr ₹439.66 Cr ₹391.36 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹64.26 Cr ₹12.83 Cr -₹55.14 Cr -₹9.51 Cr -₹15.41 Cr -₹1.24 Cr -₹11.16 Cr
Employee Benefit Expense ₹341.14 Cr ₹272 Cr ₹257.06 Cr ₹201.79 Cr ₹182.47 Cr ₹149.74 Cr ₹123.56 Cr
Finance Costs ₹23.95 Cr ₹8.3 Cr ₹14 Cr ₹13.07 Cr ₹13.5 Cr ₹17.9 Cr ₹21.57 Cr
Depreciation & Amortisation ₹91.74 Cr ₹65.55 Cr ₹59.7 Cr ₹52.78 Cr ₹49.04 Cr ₹39.68 Cr ₹31.28 Cr
Other Expenses ₹351.84 Cr ₹293.93 Cr ₹261.65 Cr ₹239.34 Cr ₹203.84 Cr ₹201.94 Cr ₹157.07 Cr
Total Expenses ₹1,564.17 Cr ₹1,227.42 Cr ₹1,169.69 Cr ₹985.2 Cr ₹870.99 Cr ₹847.67 Cr ₹713.67 Cr
Profit Before Exceptional Items & Tax ₹488.98 Cr ₹269.93 Cr ₹401.44 Cr ₹215.75 Cr ₹82.16 Cr ₹105.33 Cr ₹52.92 Cr
Exceptional Items ₹0 ₹76.4 Cr ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹488.98 Cr ₹346.33 Cr ₹401.44 Cr ₹215.75 Cr ₹82.16 Cr ₹105.33 Cr ₹52.92 Cr
Total Tax Expense ₹124.98 Cr ₹86.22 Cr ₹101.36 Cr ₹52.23 Cr ₹18.34 Cr ₹24.7 Cr ₹36.71 Cr
Net Profit ₹364 Cr ₹260.11 Cr ₹300.08 Cr ₹163.52 Cr ₹63.82 Cr ₹80.63 Cr ₹16.21 Cr
  attributable to Owners ₹364 Cr ₹0 ₹0 - - - -
  attributable to NCI ₹0 ₹0 ₹0 - - - -
Other Comprehensive Income ₹1.06 Cr -₹4.48 Lakh ₹1.36 Cr -₹3.51 Cr -₹5.93 Cr -₹1.56 Cr -₹43.4 Lakh
Total Comprehensive Income ₹365.06 Cr ₹260.06 Cr ₹301.44 Cr ₹160.01 Cr ₹57.89 Cr ₹79.07 Cr ₹15.78 Cr
EBITDA (computed) ₹604.66 Cr ₹343.77 Cr ₹475.13 Cr ₹281.59 Cr ₹144.7 Cr ₹162.91 Cr ₹105.78 Cr
Basic EPS ₹283.71 ₹202.74 ₹233.89 ₹127.45 ₹49.74 ₹62.85 ₹12.63
Diluted EPS ₹283.71 ₹202.74 ₹233.89 ₹127.45 ₹49.74 ₹62.85 ₹12.63
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,930.14 Cr ₹2,179.88 Cr ₹1,832.56 Cr ₹1,579.76 Cr
Non-current Assets ₹1,447.01 Cr ₹1,040.38 Cr ₹911.48 Cr ₹818.87 Cr
Current Assets ₹1,483.13 Cr ₹1,139.5 Cr ₹921.08 Cr ₹760.89 Cr
Property, Plant & Equipment ₹892.29 Cr ₹673.71 Cr ₹522.72 Cr ₹457.43 Cr
Inventories ₹510.29 Cr ₹385.76 Cr ₹350.42 Cr ₹279.23 Cr
Trade Receivables ₹541.35 Cr ₹315.72 Cr ₹373.53 Cr ₹361.77 Cr
Cash & Equivalents ₹76.67 Cr ₹131.93 Cr ₹87.58 Cr ₹45.42 Cr
Equity (Net Worth) ₹1,874.47 Cr ₹1,524.81 Cr ₹1,282.7 Cr ₹994.1 Cr
Equity Share Capital ₹12.9 Cr ₹12.9 Cr ₹12.9 Cr ₹12.9 Cr
Borrowings (Non-current) ₹160.95 Cr ₹90.73 Cr ₹44.92 Cr ₹74.25 Cr
Borrowings (Current) ₹35.67 Cr ₹45.28 Cr ₹37.59 Cr ₹47.26 Cr
Total Debt (computed) ₹196.61 Cr ₹136.01 Cr ₹82.51 Cr ₹121.51 Cr
Current Liabilities ₹710.2 Cr ₹465.69 Cr ₹427.68 Cr ₹438.96 Cr
Total Liabilities ₹1,055.66 Cr ₹655.08 Cr ₹549.86 Cr ₹585.67 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹346.68 Cr ₹317.38 Cr ₹261.18 Cr ₹237.21 Cr ₹58.58 Cr
Investing Cash Flow -₹423.73 Cr -₹298.16 Cr -₹149.69 Cr -₹61.5 Cr -₹93.71 Cr
Financing Cash Flow ₹20.98 Cr ₹24.96 Cr -₹69.28 Cr -₹135.8 Cr ₹37.72 Cr
Capital Expenditure ₹390.17 Cr ₹206.46 Cr ₹141.46 Cr ₹65.69 Cr ₹95.88 Cr
Free Cash Flow (computed) -₹43.49 Cr ₹110.92 Cr ₹119.72 Cr ₹171.52 Cr -₹37.3 Cr
Dividends Paid ₹15.4 Cr ₹17.96 Cr ₹12.83 Cr ₹6.41 Cr ₹3.85 Cr
Net Change in Cash -₹55.26 Cr ₹44.35 Cr ₹42.21 Cr ₹39.92 Cr ₹2.66 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹776.25 Cr ₹439.71 Cr ₹514.27 Cr ₹292.75 Cr ₹328.36 Cr ₹398.03 Cr ₹310.84 Cr ₹439.6 Cr ₹385.01 Cr ₹392.83 Cr ₹417.75 Cr ₹362.99 Cr
Other Income ₹12.46 Cr ₹8.05 Cr ₹1.8 Cr ₹7.86 Cr ₹7.46 Cr ₹3.91 Cr ₹4.33 Cr ₹4.81 Cr ₹5.36 Cr ₹2.1 Cr ₹3.05 Cr ₹2.04 Cr
Total Income ₹788.71 Cr ₹447.76 Cr ₹516.07 Cr ₹300.61 Cr ₹335.82 Cr ₹401.94 Cr ₹315.18 Cr ₹444.41 Cr ₹390.37 Cr ₹394.93 Cr ₹420.8 Cr ₹365.03 Cr
Cost of Materials Consumed ₹230.79 Cr ₹199.86 Cr ₹227.64 Cr ₹161.48 Cr ₹141.24 Cr ₹145.44 Cr ₹133.17 Cr ₹154.95 Cr ₹174.98 Cr ₹153.45 Cr ₹139.13 Cr ₹164.86 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹38.5 Cr -₹10.8 Cr -₹44.03 Cr -₹47.94 Cr -₹14.34 Cr ₹20.95 Cr -₹15.7 Cr ₹21.93 Cr -₹37.47 Cr -₹11.22 Cr ₹12.78 Cr -₹19.24 Cr
Employee Benefit Expense ₹98.47 Cr ₹88.83 Cr ₹80.37 Cr ₹73.47 Cr ₹66.46 Cr ₹69.34 Cr ₹63.07 Cr ₹73.14 Cr ₹62.49 Cr ₹65.73 Cr ₹68.96 Cr ₹59.89 Cr
Finance Costs ₹7.21 Cr ₹6.79 Cr ₹5.37 Cr ₹4.58 Cr ₹2.35 Cr ₹2.22 Cr ₹1.06 Cr ₹2.67 Cr ₹3.61 Cr ₹3.74 Cr ₹4.43 Cr ₹2.21 Cr
Depreciation & Amortisation ₹25.09 Cr ₹23.92 Cr ₹22.54 Cr ₹20.19 Cr ₹16.89 Cr ₹16.3 Cr ₹16.07 Cr ₹16.28 Cr ₹16.46 Cr ₹15.14 Cr ₹14.51 Cr ₹13.59 Cr
Other Expenses ₹101.16 Cr ₹84.69 Cr ₹94.75 Cr ₹71.25 Cr ₹83.93 Cr ₹75.71 Cr ₹68.08 Cr ₹66.22 Cr ₹78.09 Cr ₹63.6 Cr ₹59.4 Cr ₹60.56 Cr
Total Expenses ₹501.21 Cr ₹393.29 Cr ₹386.64 Cr ₹283.04 Cr ₹296.52 Cr ₹329.95 Cr ₹265.75 Cr ₹335.19 Cr ₹298.16 Cr ₹290.45 Cr ₹299.2 Cr ₹281.87 Cr
Profit Before Exceptional Items & Tax ₹287.49 Cr ₹54.48 Cr ₹129.44 Cr ₹17.57 Cr ₹39.3 Cr ₹71.99 Cr ₹49.42 Cr ₹109.22 Cr ₹92.2 Cr ₹104.48 Cr ₹121.59 Cr ₹83.16 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹55.78 Cr ₹0 ₹20.63 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹287.49 Cr ₹54.48 Cr ₹129.44 Cr ₹17.57 Cr ₹39.3 Cr ₹127.76 Cr ₹49.42 Cr ₹129.84 Cr ₹92.2 Cr ₹104.48 Cr ₹121.59 Cr ₹83.16 Cr
Total Tax Expense ₹74.82 Cr ₹13.9 Cr ₹32.58 Cr ₹3.67 Cr ₹11.49 Cr ₹26.18 Cr ₹16.58 Cr ₹31.97 Cr ₹24.64 Cr ₹23.09 Cr ₹32.35 Cr ₹21.28 Cr
Net Profit ₹212.67 Cr ₹40.57 Cr ₹96.85 Cr ₹13.9 Cr ₹27.81 Cr ₹101.59 Cr ₹32.84 Cr ₹97.87 Cr ₹67.56 Cr ₹81.39 Cr ₹89.25 Cr ₹61.88 Cr
  attributable to Owners ₹212.67 Cr ₹40.57 Cr ₹0 ₹13.9 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹1.24 Cr -₹16.34 Lakh -₹10.83 Lakh ₹9.92 Lakh ₹20.36 Lakh -₹25,000 -₹23.83 Lakh -₹76,000 ₹88.83 Lakh ₹8.25 Lakh ₹40.28 Lakh -₹1.43 Lakh
Total Comprehensive Income ₹213.91 Cr ₹40.41 Cr ₹96.75 Cr ₹14 Cr ₹28.01 Cr ₹101.58 Cr ₹32.6 Cr ₹97.87 Cr ₹68.45 Cr ₹81.47 Cr ₹89.65 Cr ₹61.86 Cr
EBITDA (computed) ₹319.79 Cr ₹85.19 Cr ₹157.35 Cr ₹42.34 Cr ₹58.54 Cr ₹90.5 Cr ₹66.56 Cr ₹128.17 Cr ₹112.27 Cr ₹123.37 Cr ₹140.54 Cr ₹98.96 Cr
Basic EPS ₹165.76 ₹31.62 ₹75.49 ₹10.83 ₹21.67 ₹79.18 ₹25.60 ₹76.28 ₹52.66 ₹63.44 ₹69.56 ₹48.23
Diluted EPS ₹165.76 ₹31.62 ₹75.49 ₹10.83 ₹21.67 ₹79.18 ₹25.60 ₹76.28 ₹52.66 ₹63.44 ₹69.56 ₹48.23
Latest 12 quarters shown of 25 on record.
Segment · Q3 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
India ₹91.59 Cr ₹0 ₹1,333.2 Cr ₹0
Europe ₹121.99 Cr ₹0 ₹0 ₹0
USA and North America ₹191.8 Cr ₹0 ₹0 ₹0
Rest of the world ₹34.33 Cr ₹0 ₹3.28 Lakh ₹0
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,022.99 Cr ₹1,476.84 Cr ₹1,558.58 Cr ₹1,191.2 Cr ₹951.08 Cr ₹936.91 Cr ₹762.71 Cr
Other Income ₹30.16 Cr ₹20.51 Cr ₹12.54 Cr ₹9.75 Cr ₹2.08 Cr ₹16.09 Cr ₹3.89 Cr
Total Income ₹2,053.15 Cr ₹1,497.35 Cr ₹1,571.12 Cr ₹1,200.95 Cr ₹953.15 Cr ₹953.01 Cr ₹766.6 Cr
Cost of Materials Consumed ₹819.76 Cr ₹574.81 Cr ₹632.43 Cr ₹487.74 Cr ₹437.55 Cr ₹439.66 Cr ₹391.36 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹64.26 Cr ₹12.83 Cr -₹55.14 Cr -₹9.51 Cr -₹15.41 Cr -₹1.24 Cr -₹11.16 Cr
Employee Benefit Expense ₹328.82 Cr ₹261.4 Cr ₹248.53 Cr ₹194.84 Cr ₹175.76 Cr ₹144.02 Cr ₹118.48 Cr
Finance Costs ₹23.95 Cr ₹8.3 Cr ₹14 Cr ₹13.07 Cr ₹13.49 Cr ₹17.9 Cr ₹21.57 Cr
Depreciation & Amortisation ₹91.73 Cr ₹65.54 Cr ₹59.7 Cr ₹52.78 Cr ₹49.04 Cr ₹39.68 Cr ₹31.28 Cr
Other Expenses ₹365.42 Cr ₹305.5 Cr ₹270.84 Cr ₹246.82 Cr ₹210.99 Cr ₹208.04 Cr ₹162.57 Cr
Total Expenses ₹1,565.42 Cr ₹1,228.38 Cr ₹1,170.36 Cr ₹985.73 Cr ₹871.41 Cr ₹848.05 Cr ₹714.1 Cr
Profit Before Exceptional Items & Tax ₹487.73 Cr ₹268.97 Cr ₹400.77 Cr ₹215.21 Cr ₹81.74 Cr ₹104.96 Cr ₹52.5 Cr
Exceptional Items ₹0 ₹76.4 Cr ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹487.73 Cr ₹345.37 Cr ₹400.77 Cr ₹215.21 Cr ₹81.74 Cr ₹104.96 Cr ₹52.5 Cr
Total Tax Expense ₹124.63 Cr ₹85.95 Cr ₹101.17 Cr ₹52.09 Cr ₹18.21 Cr ₹24.67 Cr ₹36.62 Cr
Net Profit ₹363.11 Cr ₹259.43 Cr ₹299.6 Cr ₹163.12 Cr ₹63.53 Cr ₹80.29 Cr ₹15.88 Cr
Other Comprehensive Income ₹35.16 Lakh -₹21.19 Lakh ₹1.41 Cr -₹3.91 Cr -₹5.99 Cr -₹1.39 Cr -₹78.74 Lakh
Total Comprehensive Income ₹363.46 Cr ₹259.21 Cr ₹301 Cr ₹159.21 Cr ₹57.54 Cr ₹78.9 Cr ₹15.09 Cr
EBITDA (computed) ₹603.41 Cr ₹342.81 Cr ₹474.47 Cr ₹281.06 Cr ₹144.27 Cr ₹162.54 Cr ₹105.34 Cr
Basic EPS ₹283.01 ₹202.20 ₹233.51 ₹127.14 ₹49.52 ₹62.58 ₹12.38
Diluted EPS ₹283.01 ₹202.20 ₹233.51 ₹127.14 ₹49.52 ₹62.58 ₹12.38
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,928.34 Cr ₹2,178.17 Cr ₹1,830.93 Cr ₹1,579.34 Cr
Non-current Assets ₹1,446.97 Cr ₹1,040.35 Cr ₹911.46 Cr ₹819 Cr
Current Assets ₹1,481.37 Cr ₹1,137.82 Cr ₹919.47 Cr ₹760.34 Cr
Property, Plant & Equipment ₹892.27 Cr ₹673.69 Cr ₹522.71 Cr ₹457.43 Cr
Inventories ₹510.29 Cr ₹385.76 Cr ₹350.42 Cr ₹279.23 Cr
Trade Receivables ₹541.35 Cr ₹315.72 Cr ₹373.53 Cr ₹361.77 Cr
Cash & Equivalents ₹75.31 Cr ₹130.38 Cr ₹86.07 Cr ₹44.96 Cr
Equity (Net Worth) ₹1,865.85 Cr ₹1,517.79 Cr ₹1,276.54 Cr ₹988.36 Cr
Equity Share Capital ₹12.9 Cr ₹12.9 Cr ₹12.9 Cr ₹12.9 Cr
Borrowings (Non-current) ₹160.95 Cr ₹90.73 Cr ₹44.92 Cr ₹74.25 Cr
Borrowings (Current) ₹35.67 Cr ₹45.28 Cr ₹37.59 Cr ₹47.26 Cr
Total Debt (computed) ₹196.61 Cr ₹136.01 Cr ₹82.51 Cr ₹121.51 Cr
Current Liabilities ₹719.24 Cr ₹472.84 Cr ₹433.8 Cr ₹445.75 Cr
Total Liabilities ₹1,062.49 Cr ₹660.38 Cr ₹554.39 Cr ₹590.97 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹347.58 Cr ₹317.49 Cr ₹260.06 Cr ₹238.53 Cr ₹58.6 Cr
Investing Cash Flow -₹423.74 Cr -₹298.14 Cr -₹149.67 Cr -₹61.5 Cr -₹93.72 Cr
Financing Cash Flow ₹20.98 Cr ₹24.96 Cr -₹69.28 Cr -₹135.8 Cr ₹37.72 Cr
Capital Expenditure ₹390.17 Cr ₹206.45 Cr ₹141.44 Cr ₹65.69 Cr ₹95.89 Cr
Free Cash Flow (computed) -₹42.59 Cr ₹111.04 Cr ₹118.62 Cr ₹172.84 Cr -₹37.29 Cr
Dividends Paid ₹15.4 Cr ₹17.96 Cr ₹12.83 Cr ₹6.41 Cr ₹3.85 Cr
Net Change in Cash -₹55.07 Cr ₹44.31 Cr ₹41.11 Cr ₹41.24 Cr ₹2.6 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹776.25 Cr ₹439.71 Cr ₹514.27 Cr ₹292.75 Cr ₹328.36 Cr ₹398.03 Cr ₹310.84 Cr ₹439.6 Cr ₹385.01 Cr ₹392.83 Cr ₹417.75 Cr ₹362.99 Cr
Other Income ₹12.46 Cr ₹8.05 Cr ₹1.8 Cr ₹7.86 Cr ₹7.46 Cr ₹3.91 Cr ₹4.33 Cr ₹4.81 Cr ₹5.36 Cr ₹2.1 Cr ₹3.05 Cr ₹2.04 Cr
Total Income ₹788.71 Cr ₹447.76 Cr ₹516.07 Cr ₹300.61 Cr ₹335.82 Cr ₹401.94 Cr ₹315.18 Cr ₹444.41 Cr ₹390.37 Cr ₹394.93 Cr ₹420.8 Cr ₹365.03 Cr
Cost of Materials Consumed ₹230.79 Cr ₹199.86 Cr ₹227.64 Cr ₹161.48 Cr ₹141.24 Cr ₹145.44 Cr ₹133.17 Cr ₹154.95 Cr ₹174.98 Cr ₹153.45 Cr ₹139.13 Cr ₹164.86 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹38.5 Cr -₹10.8 Cr -₹44.03 Cr -₹47.94 Cr -₹14.34 Cr ₹20.95 Cr -₹15.7 Cr ₹21.93 Cr -₹37.47 Cr -₹11.22 Cr ₹12.78 Cr -₹19.24 Cr
Employee Benefit Expense ₹95.27 Cr ₹85.99 Cr ₹76.68 Cr ₹70.88 Cr ₹64.19 Cr ₹67.21 Cr ₹59.03 Cr ₹70.97 Cr ₹61.01 Cr ₹63.34 Cr ₹66.49 Cr ₹57.7 Cr
Finance Costs ₹7.23 Cr ₹6.79 Cr ₹5.34 Cr ₹4.58 Cr ₹2.35 Cr ₹2.22 Cr ₹1.06 Cr ₹2.67 Cr ₹3.61 Cr ₹3.74 Cr ₹4.43 Cr ₹2.21 Cr
Depreciation & Amortisation ₹25.09 Cr ₹23.92 Cr ₹22.54 Cr ₹20.19 Cr ₹16.89 Cr ₹16.3 Cr ₹16.07 Cr ₹16.28 Cr ₹16.46 Cr ₹15.14 Cr ₹14.51 Cr ₹13.59 Cr
Other Expenses ₹104.79 Cr ₹87.73 Cr ₹98.86 Cr ₹74.03 Cr ₹86.51 Cr ₹78.06 Cr ₹73 Cr ₹67.93 Cr ₹79.69 Cr ₹66.69 Cr ₹62.06 Cr ₹62.4 Cr
Total Expenses ₹501.66 Cr ₹393.49 Cr ₹387.03 Cr ₹283.23 Cr ₹296.84 Cr ₹330.17 Cr ₹266.64 Cr ₹334.73 Cr ₹298.29 Cr ₹291.15 Cr ₹299.39 Cr ₹281.53 Cr
Profit Before Exceptional Items & Tax ₹287.04 Cr ₹54.27 Cr ₹129.04 Cr ₹17.38 Cr ₹38.98 Cr ₹71.77 Cr ₹48.54 Cr ₹109.68 Cr ₹92.08 Cr ₹103.78 Cr ₹121.4 Cr ₹83.5 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹55.78 Cr ₹0 ₹20.63 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹287.04 Cr ₹54.27 Cr ₹129.04 Cr ₹17.38 Cr ₹38.98 Cr ₹127.54 Cr ₹48.54 Cr ₹130.31 Cr ₹92.08 Cr ₹103.78 Cr ₹121.4 Cr ₹83.5 Cr
Total Tax Expense ₹74.52 Cr ₹13.86 Cr ₹32.58 Cr ₹3.67 Cr ₹11.25 Cr ₹26.15 Cr ₹16.58 Cr ₹31.97 Cr ₹24.47 Cr ₹23.08 Cr ₹32.34 Cr ₹21.28 Cr
Net Profit ₹212.52 Cr ₹40.42 Cr ₹96.46 Cr ₹13.71 Cr ₹27.73 Cr ₹101.39 Cr ₹31.96 Cr ₹98.34 Cr ₹67.61 Cr ₹80.7 Cr ₹89.06 Cr ₹62.22 Cr
Other Comprehensive Income ₹83.05 Lakh -₹18.62 Lakh -₹29.27 Lakh ₹0 ₹17.51 Lakh ₹0 -₹40.06 Lakh ₹1.36 Lakh ₹97.21 Lakh ₹0 ₹40.08 Lakh ₹3.5 Lakh
Total Comprehensive Income ₹213.35 Cr ₹40.23 Cr ₹96.17 Cr ₹13.71 Cr ₹27.91 Cr ₹101.39 Cr ₹31.56 Cr ₹98.35 Cr ₹68.58 Cr ₹80.7 Cr ₹89.46 Cr ₹62.26 Cr
EBITDA (computed) ₹319.36 Cr ₹84.98 Cr ₹156.92 Cr ₹42.15 Cr ₹58.22 Cr ₹90.28 Cr ₹65.67 Cr ₹128.63 Cr ₹112.15 Cr ₹122.67 Cr ₹140.35 Cr ₹99.3 Cr
Basic EPS ₹165.65 ₹31.50 ₹75.18 ₹10.68 ₹21.62 ₹79.03 ₹24.91 ₹76.65 ₹52.70 ₹62.90 ₹69.42 ₹48.50
Diluted EPS ₹165.65 ₹31.50 ₹75.18 ₹10.68 ₹21.62 ₹79.03 ₹24.91 ₹76.65 ₹52.70 ₹62.90 ₹69.42 ₹48.50
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Neuland Laboratories Ltd.. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Neuland Laboratories Ltd.

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 32.63%, foreign institutional investors hold 20.46%, domestic institutional investors hold 15.84%, retail and other public shareholders hold 31.07% of Neuland Laboratories Ltd.. The company had 46,304 shareholders on record.

Promoters: 32.63%DII (Domestic Institutional): 15.84%FII (Foreign Institutional): 20.46%Retail & Others: 31.07%
Mar 2026
QUARTER
32.63% Promoters
15.84% DII (Domestic Institutional)
20.46% FII (Foreign Institutional)
31.07% Retail & Others
Promoter holding - history
Now 32.63% · Mar 2026High 51.69% · Dec 2015Low 32.63% · Dec 2025
31%36.5%42%47.5%53%Dec 2015Apr 2018Jun 2020Dec 2022Jun 2025Dec 2015: 51.69%Mar 2016: 51.69%Jun 2016: 51.69%Sep 2016: 51.69%Dec 2016: 51.68%Mar 2017: 51.68%Jun 2017: 51.68%Sep 2017: 51.68%Dec 2017: 51.68%Mar 2018: 51.68%Apr 2018: 41.46%May 2018: 36.04%Jun 2018: 36.04%Sep 2018: 36.04%Dec 2018: 36.04%Mar 2019: 35.90%Jun 2019: 35.90%Sep 2019: 35.86%Dec 2019: 35.86%Mar 2020: 36.20%Jun 2020: 36.27%Sep 2020: 36.25%Dec 2020: 36.25%Mar 2021: 36.22%Jun 2021: 36.22%Sep 2021: 36.22%Dec 2021: 36.22%Mar 2022: 36.22%Jun 2022: 36.22%Sep 2022: 36.22%Dec 2022: 36.14%Mar 2023: 36.14%Jun 2023: 36.03%Sep 2023: 35.97%Dec 2023: 32.80%Mar 2024: 32.74%Jun 2024: 32.72%Sep 2024: 32.64%Dec 2024: 32.68%Mar 2025: 32.68%Jun 2025: 32.68%Sep 2025: 32.64%Dec 2025: 32.63%Mar 2026: 32.63%51.69%32.63%32.63%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters32.63%32.63%32.64%32.68%32.68%32.68%
Public67.37%67.37%67.36%67.32%67.32%67.32%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters32.63%32.68%32.74%36.14%36.22%36.22%36.20%35.90%51.68%51.68%51.69%
Public67.37%67.32%67.26%63.86%63.78%63.78%63.80%64.10%48.32%48.32%48.31%
Promoter change (YoY, %pts)-0.05-0.06-3.40-0.08+0.00+0.02+0.30-15.78+0.00-0.01-

Board & Governance of Neuland Laboratories Ltd.

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Neuland Laboratories Ltd. has 8 directors - 5 independent and 3 executive. The board is chaired by Davuluri Rama Mohan Rao.

DirectorPositionOn board sinceListed boards
Davuluri Rama Mohan Rao Executive Director · Chairperson 1984-07-01 1
Davuluri Sucheth Rao Executive Director · CEO 2003-07-29 1
Davuluri Saharsh Rao Executive Director · MD 2009-05-21 1
Christopher M Cimarusti Non-Executive - Non Independent Director 2009-10-20 1
Homi Rustam Khusrokhan Non-Executive - Independent Director 2019-02-12 2
Prasad Raghava Menon Non-Executive - Independent Director 2022-10-31 3
Sugata Sircar Non-Executive - Independent Director 2023-06-27 1
Pallavi Joshi Bhakru Non-Executive - Independent Director 2023-06-27 4
Ravi Shankar Gopinath Non-Executive - Independent Director 2025-08-01 2
Board Committees
CommitteeMembers
Audit Committee Homi Rustam Khusrokhan (Chairperson), Sugata Sircar, Pallavi Joshi Bhakru, Prasad Raghava Menon
Nomination and remuneration committee Homi Rustam Khusrokhan (Chairperson), Prasad Raghava Menon, Pallavi Joshi Bhakru
Stakeholders Relationship Committee Pallavi Joshi Bhakru (Chairperson), Davuluri Sucheth Rao, Davuluri Saharsh Rao
Risk Management Committee Prasad Raghava Menon (Chairperson), Homi Rustam Khusrokhan, Davuluri Sucheth Rao, Davuluri Saharsh Rao, Ravi Shankar Gopinath
Corporate Social Responsibility Committee Prasad Raghava Menon (Chairperson), Davuluri Rama Mohan Rao, Davuluri Sucheth Rao, Davuluri Saharsh Rao, Pallavi Joshi Bhakru

Charges & Borrowings of Neuland Laboratories Ltd.

Open charges
₹1,221.88 Cr
Satisfied charges
₹2,289.23 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹1,088.75 Cr
Hdfc Bank Limited₹130.00 Cr
Axis Bank Limited₹3.13 Cr
Latest charge details
DateLenderAmountStatus
22 Dec 2025 Hdfc Bank Limited ₹130 Cr Open
27 Nov 2023 Axis Bank Limited ₹2.71 Cr Open
29 Jul 2022 Sbicap Trustee Company Limited ₹1,088.75 Cr Open
22 Jul 2020 Axis Bank Limited ₹42.4 Lakh Open
18 Mar 2025 Others ₹190 Cr Satisfied

Total charge records: 63 View all charges

Employees and EPFO Compliance at Neuland Laboratories Ltd.

Neuland Laboratories Ltd. has a workforce of 1,860 employees as of Apr 02, 2024.

Employee count
1,860
Active EPFO establishments
2
Employee growth
1.69%
Premium access

Employee and EPFO history for Neuland Laboratories Ltd.

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Neuland Laboratories Ltd.

Premium access

GST registrations and filing compliance for Neuland Laboratories Ltd.

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Neuland Laboratories Ltd.

Premium access

Credit ratings, litigation, and regulatory alerts for Neuland Laboratories Ltd.

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Neuland Laboratories Ltd.

Premium access

MSME payment history for Neuland Laboratories Ltd.

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Neuland Laboratories Ltd.

Premium access

Corporate group structure for Neuland Laboratories Ltd.

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Neuland Laboratories Ltd.

Premium access

MCA filings and documents for Neuland Laboratories Ltd.

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Neuland Laboratories Ltd.

Directors
12 May 2026
Mauricio Futran was appointed as a Additional Director on 12 May 2026 & has been associated with this company since 3 months 10 days.
Charges
22 Dec 2025
A charge with Hdfc Bank Limited amounted to Rs. 130.00 Cr with Charge ID 101213000 was registered on 22 Dec 2025.
Charges
18 Nov 2025
A charge registered on 18 Mar 2025 via Charge ID 101076510 with Others was fully satisfied on 18 Nov 2025.
Charges
27 Oct 2025
A charge with Sbicap Trustee Company Limited of Rs. 1,088.75 Cr registered on 29 Jul 2022 with Charge ID 100603089 was modified on 27 Oct 2025.
Directors
01 Aug 2025
Ravi Shankar Gopinath was appointed as a Director on 01 Aug 2025 & has been associated with this company since 1 year 19 days.
Activity
30 Jul 2025
Neuland Laboratories Ltd. last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records.

Recent News on Neuland Laboratories Ltd.

Stocks that will see action today: December 13, 2024
13 Dec 2024 · Thehindubusinessline

Frequently Asked Questions about Neuland Laboratories Ltd.

Neuland Laboratories Ltd. is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 07 January 1984 (42+ years old) and is registered under CIN L85195TG1984PLC004393. Listed on BSE: 524558 and NSE: NEULANDLAB. The company has 1,860 employees.

Neuland Laboratories Ltd. reported revenue of ₹2,022.99 Cr for FY 2026 (up 36.98% YoY) based on consolidated NSE filings.

The current directors of Neuland Laboratories Ltd. are:

The primary industry of Neuland Laboratories Ltd. is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Neuland Laboratories Ltd. is listed on both BSE (code: 524558) and NSE (symbol: NEULANDLAB).

Neuland Laboratories Ltd. can be reached at the registered office: 11Th Floor 5Th Level Phoenix Ivy Building Plot No. 573A – Iii Road No. 82 Jubilee, Hills, Hyderabad, Telangana, India – 500033, or through the website neulandlabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available